A clinical trial to study the effects of hingwadi tail matrabasti and mefenamic acid in patients with dysmenorrhea

Evaluation of comparative efficacy of Hingwadi tail matrabasti versus Mefenamic acid in management of Kashtartava (primary spasmodic dysmenorrhea) - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055239

Enrollment

110

Registered

2023-07-14

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as primary spasmodic dysmenorrhoea. 2. Patients complaining painful menstruation for first two days for two Consecutive cycles. 3. Patients having regular menstrual cycles.

Exclusion criteria

Exclusion criteria: 1. Patients with major systemic diseases. 2. Patients having congenital anomalies leading to dysmenorrhea. 3. Patients having any detectable organic pelvic pathology. 4. Patients on hormonal therapy

Design outcomes

Primary

Measure	Time frame
Primary outcome measure: change in subjective parameter like abdominal Pain during menstruation, waist-hip pain, Low backache, Duration of Pain, Nausea, Vomiting, fatigue, diarrhea, headache.Timepoint: assess after 3 consecutive menstrual cycles	—

Secondary

Measure	Time frame
Secondary outcome measure: change in objective parameter VASTimepoint: assess after 3 consecutive menstrual cycles	—

Countries

India

Contacts

Public ContactDr Priya chawle

Mahatma Gandhi Ayurved College Hospital and Research Centre, Salod, Wardha

devyanidasar06@gmail.com8080403738

Outcome results